Deep Pujara retweeted
ATLAS meta-analysis of 6 trials on EVT for large core infarcts confirms large treatment effect of EVT, reducing disability and mortality, with a NNT of 4,2.
Treatment benefit was consistent over clinical and most imaging subgroups.
@ESOstroke #VoiceOfStroke #Stroke #ESOC2026
Deep Pujara retweeted
Presenting at #ESOC2026, the ATLAS study found endovascular thrombectomy was associated with improved functional outcomes & reduced mortality vs medical management in patients with large-core ischaemic stroke presenting within 24h of onset.
spkl.io/6016A7GFg @ESOstroke

ALT Research in context panel for paper published in The Lancet entitled \"Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data metaanalysis\nwith central imaging adjudication\". Copyright: 2026 Elsevier Ltd. All rights reserved.
Deep Pujara retweeted
On behalf of the large core trials principal investigators, immensely proud and honored to present primary results of the ATLAS IPD meta-analysis @ESOstroke with simultaneous publication in
@TheLancet -thelancet.com/journals/lance…
EVT not only improved outcomes compared to medical care, but functional independence and independent ambulation were also achieved in a meaningful proportion of patients. Additionally, EVT was life-saving, as one of the few reperfusion therapies to achieve it. With the exception of patients with very large core (volume ≥150 ml) in the late time window, where evidence is limited because of wide confidence intervals but benefit could not be excluded, EVT demonstrated consistent benefit regardless of ASPECTS and ischaemic core strata.
Our deepest gratitude to the patients, their families, and all investigators and coordinators at the trial sites. A mammoth collective effort over 3 years from 6 trials with practice changing results that improve care for 20% LVOs! #stroke #EVT #largecore #NoLVOleftbehind @XiaochuanHuo @VCostalat @oozaidat @VYogendrakumar @deeppujara @dliebesk @ARazzakMD @NguyenThanhMD @samialkasab @AmeerEHassan @Michael3Abraham @FelixSun1230 @HiroshiYamagam2 @SunilAShethMD @Fie0815 @RaulNogueiraMD @rgrandhi @PascalJabbourMD @shazamhussain @dr_mchen @mihill68 @lapergue6 @TudorGJovin @AlbertJYoo
Deep Pujara retweeted
Women Benefit Equally From Endovascular Thrombectomy for Large Core Ischemic Stroke in a Subanalysis of SELECT2
In this #BloggingStroke post, @drchloemutimer discusses #Stroke article by @JPTsaiMD et al. #AHAJournals #GoRedForWomen
ahajournals.org/do/10.1161/b…
Deep Pujara retweeted
Congratulations to @JPTsaiMD on leading the analysis on sex-based differences in EVT outcomes for large strokes from @SELECT2Trial, published in @StrokeAHA_ASA's #GoRedforWomen collection. No significant heterogeneity in EVT benefits across sexes. Age and ischemic core size remained prognostic in both males and females.@NguyenThanhMD @deeppujara @johannatfifi @Michael3Abraham @dr_mchen @shazamhussain @CerebrovascLab @aopaskar @marcriboj @AmeerEHassan @StavTjoumakaris @mihill68 @natperezossa @anjailibrahim @fournier_lauren @NeuroFaris
#STROKE: In a post hoc analysis of the SELECT-2 trial, both biological sexes enjoyed equal benefit from EVT in the setting of established large core infarction. #AHAJournals #GoRedforWomen
ahajournals.org/doi/abs/10.1…
Deep Pujara retweeted
.@UHhospitals has been awarded US$7 million in research funding by @PCORI to evaluate endovascular #Thrombectomy in patients presenting more than 24 hours from time last known well via the global SELECT LATE clinical trial
@amrsarrajMD @SELECT2Trial
neuronewsinternational.com/s…
Deep Pujara retweeted
Honored and grateful for the opportunity to assess the role of Endovascular Thrombectomy beyond 24 hours of last known well through SELECT LATE international, multicenter pragmatic clinical trial - pcori.org/research-results/2… funded by @PCORI @UHhospitals
Excited to collaborate with my Co-Investigators Bruce Campbell @UniMelb, Jeff Saver @UCLANeurology, Jim Grotta @memorialhermann, @NguyenThanhMD @The_BMC, @StavTjoumakaris @TJUHNeurosurg, Steve Messe @PennNeurology, Leonid Churilov @UniMelb and Clark Sitton @McGovernMed for the successful conduct of the trial.
Grateful to our stakeholders @MitchElkind, @AmeerEHassan, @dr_mchen, Erin Supan, Eric Hess, Daniel Ellenberger and patients’ advocates Christina Globuski, Matthew and Laura Antenucci, James and Jessica Sulecki and Kelly Montgomery for their guidance on how to make our study more pragmatic and patient-centered.
Deep Pujara retweeted
Congratulations @AmeerEHassan @Michael3Abraham on leading analyses on effect of procedure characteristics and reperfusion success on EVT outcomes for patients with large strokes from @SELECT2Trial onlinelibrary.wiley.com/doi/… @ANA_journals ~80% procedural success that improved clinical outcomes and reduced infarct growth. eTICI 2c-3 improved outcomes compared to those with eTICI 2b. Prolonged procedures were associated with worse outcomes. Consistent results across aspiration first vs stent retriever approaches.
@shazamhussain, @CerebrovascLab, @dr_mchen, @deeppujara, @NabeelHerial, @JPTsaiMD, @DrPatchiz, @drricardohanel, @almuftifawaz, @AndrewKCheung, @jordiblascoa, @LUISANROMA, @NiravAVora, @DanSahlein, @LElijovich, @ArenillasJF, @Teddyyhwu, @PCardonaP, @natperezossa, @JoannaSchaafsma, @BJHicksMD, @NaviSSangha, @warach_steven, @TimothyKleinig, @Faris_Shaker, @FreqFrequentist, @wondeasa, @mark_dannenbaum, @GaborTothMD, @AmuluruKrishna, @JanKarlBurkhar1, @ARazzakMD, @HarisKamalMD, @vitorpereiracan, @NguyenThanhMD, @Johannatfifi, @esamaniego, @AdamArthurMD, @StavTjoumakaris, @PascalJabbourMD, @jimgrotta, @mihill68, @marcriboj
Deep Pujara retweeted
Our comprehensive review @ANA_journals on current neuroimaging evidence for reperfusion therapies, shifting treatment paradigms and utility of different imaging modalities in acute ischemic stroke. @DrBruceCampbell @deeppujara
onlinelibrary.wiley.com/doi/…
Deep Pujara retweeted
Honored to receive the 2024 Clinical Research Forum top 10 award on behalf of @SELECT2Trial investigators.Inspiring & motivational to see exciting progress on many healthcare fronts by elite clinician scientists.This recognition motivates us to keep pushing boundaries @CRForumUS
Deep Pujara retweeted
🎯 Major Findings in Stroke 🌟
Hopeful twist in recovery! Despite 75% patients experience intracranial hemorrhage post-EVT, functional outcomes remain unaffected. 🧠💪 SELECT2 trial shows hemorrhages are not the end of the road! 🚀
Read the full study 👉 bit.ly/3xf5tfu
Deep Pujara retweeted
Proud and honored to present @SELECT2Trial results at #ISC2023 EVT is safe and efficacious in large core! We’re a step closer to improving more patients lives. nejm.org/doi/full/10.1056/NE…
Deep Pujara retweeted
Our latest @JAMANeuro “SELECT Late” international cohort study; EVT was associated with increased odds of functional independence in selected patients treated beyond 24 hours of last known well #NoLVOleftbehind #stroke #neurology jamanetwork.com/journals/jam…
Deep Pujara retweeted
We’ve made it to 800 followers. Be apart if the conversation by sharing and commenting on ACTN and Annals of Neurology publications on Twitter. Help us make it to 1000 followers. Tag a friend who shouldn’t miss out! @TheNewANA1 @AANmember.
Deep Pujara retweeted
Hello #NeuroTwitter
Join us in welcoming our awesome residency program director, @DCPneuro to the world of #Twitter 🥳
It took a long time convincing him, so show him some love 🧠❤️
#NeurologyProud @AANEMorg @AANMember #Neurology #Residency @NMatch2023
Deep Pujara retweeted
I sit with the legendary @jimgrotta to discuss #BEST-MSU. MSU 🚑 provides faster thrombolysis, enhances #stroke outcomes, shortens time to EVT and is cost-effective. This world renowned strokologist, and my mentor, is a great listen. Like an old wine, only gets better with age!
Amrou Sarraj, MD, interviews James Grotta, MD, on the trial design & execution of the recently published BEST-MSU clinical trial analyzing the benefit of prehospital stroke treatment delivered through a mobile stroke unit. @amrsarrajMD #neurotwitter okt.to/vrJZlY
Deep Pujara retweeted
sciencedirect.com/science/ar…
Our #latest meta-analysis+review on direct carotid access when it is absolutely necessary to go north & giving up is not an option!#GTFVO #NeverBackDown @visishs @almuftifawaz @KunalVakhariaMD @amrsarrajMD @svinsociety @AmeerEHassan @elghanemmoh
"Carotid sticking it to all the doubters." - @Eric_Feldstein
Huge thank you to this team for their work demonstrating the feasibility and safety of alternative transcarotid access when femoral and radial access are impractical. @almuftifawaz @NeurologyNymc @nymcbrainspine
Deep Pujara retweeted
Latest content - https://nitter.cf/t.co/lC2ZL32MvZ - Fifi et al. found women had similar discharge outcomes as men following #EVT, but the improvement from discharge to 90 days was significantly worse in women. @johannatfifi @Faris_Shaker @amrsarrajMD @StavTjoumakaris @AnneAlexandrov
Deep Pujara retweeted
❗Late breaking oral abstracts happening now #ISC22❗
Update on this trial: SELECT2 seeks to evaluate thrombectomy in patients with large core on perfusion imaging
👏 Interim analysis showed no safety concerns and will continue enrollment 👏
@amrsarrajMD
Deep Pujara retweeted
…time & start focusing on salvageable tissue w disabling deficits as primary indication for MT. More data presented today #ISC22 showing benefit of MT >24hrs by @amrsarrajMD. More data coming…@GhadaMohamedMD @aboulnourh @OwaisAlsrouji @HenryFordNeuro @AshuPJadhav @stephanamayer
























